Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have received an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $24.00.

Several analysts have weighed in on ZVRA shares. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Zacks Research cut Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. JMP Securities decreased their price objective on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. HC Wainwright initiated coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Wall Street Zen cut Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The shares were bought at an average cost of $9.16 per share, with a total value of $45,800.00. Following the acquisition, the director owned 45,000 shares in the company, valued at approximately $412,200. This represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its holdings in shares of Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after buying an additional 1,280 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Zevra Therapeutics during the 4th quarter worth approximately $53,000. GAMMA Investing LLC grew its position in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after acquiring an additional 8,020 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after acquiring an additional 8,552 shares during the last quarter. Finally, Creative Planning bought a new position in Zevra Therapeutics during the 2nd quarter worth approximately $92,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $9.75 on Friday. The business’s 50-day moving average price is $9.44 and its two-hundred day moving average price is $8.99. Zevra Therapeutics has a twelve month low of $6.19 and a twelve month high of $13.16. The stock has a market cap of $547.27 million, a P/E ratio of -46.43 and a beta of 1.49. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.